OOIR: Observatory of International Research

Papers

(The H4-Index of Nature Reviews Rheumatology is 59. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Low-dose rituximab can go even lower	680
No benefit from adding MTX to ustekinumab	435
Inflammatory arthritis affects men’s fertility	373
Bimekizumab effective across the axSpA spectrum	354
SLC26A2 deficiency, matrix stiffness and mechanotransduction linked in osteoporosis	327
Genome-wide mutagenesis reported in systemic sclerosis	274
Reply to ‘Potential benefit of anticoagulation in Behçet syndrome’	252
Rheumatic diseases on the rise	242
A role for TGFβ and EBV in MIS-C pathogenesis	222
The role of the patient in rheumatology	193
Biological and clinical roles of IL-18 in inflammatory diseases	172
COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations	169
Towards better management of sterile bone inflammation	159
New drug formulation reduces bone loss	156
Use of platelet-rich plasma for knee OA not supported by RCT results	144
FOXP3 splice variant is associated with autoimmune disease	131
To choose or not? The value of discrete-choice experiments in rheumatology	131
Urchin-like nanoparticles for miRNA therapy of OA	127
The value of comparative efficacy studies in informing rheumatology guidelines	126
The 2022 ACR vaccination guideline: a call-to-action	122
Imbalance of threat and soothing systems in fibromyalgia: rephrasing an established mechanistic model?	117
MIS-C: myths have been debunked, but mysteries remain	112
Down syndrome: insights into autoimmune mechanisms	112
Addressing the challenge of global delays in diagnosis and treatment of systemic lupus erythematosus	111
Inflammation across tissues: can shared cell biology help design smarter trials?	110

Appraising the evolving landscape of protease inhibition in osteoarthritis	104
2021 ACR guideline for JIA reflects changes in practice	103
Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician	102
Low-dose glucocorticoids benefit seniors with RA	102
Co-trimoxazole reduces mortality in anti-MDA5-DM	99
Low back pain is a growing concern	97
Wnt-induced IGF1 drives OA	91
Pain in systemic lupus erythematosus: emerging insights and paradigms	91
Guiding ILD management in systemic autoimmune rheumatic diseases	91
Publisher Correction: Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician	89
Biologics in rheumatoid arthritis: a lifetime treatment or possibility of drug holidays?	89
Author Correction: Proposals for the rheumatological use of JAK inhibitors	86
Calprotectin tracks tocilizumab-treated RA	86
A direct link between SARS-CoV-2 and bone loss	85
S100A4 inhibition targets fibrosis in SSc	84
Rheumatic diseases and metabolism: where centre and periphery meet	83
Fumarate drives interferon release in systemic sclerosis monocytes	79
Distinct mucosal endotypes as initiators and drivers of rheumatoid arthritis	78
Antibiotics keep rheumatic heart disease at bay	77
Sexual dimorphism in the prevalence, manifestation and outcomes of axial spondyloarthritis	77
Rheumatology in the digital health era: status quo and quo vadis?	77
Erosive cargo from synovial fibroblasts	72
Which DMARD for ICI-associated arthritis?	70
Targeting the IVD clock to halt degeneration	70
sCD13 role in arthritis mediated via bradykinin receptor	69
CAR T cells induce drug-free SLE remission	68
Publisher Correction: Recent advances in the diagnosis and management of neuropsychiatric lupus	67
Insights into IVDD pathogenesis in 2024	65
ERAP1 and the return of the UPR in ankylosing spondylitis	64
Macrophage-coated nanocarriers for gouty arthritis	63
A path towards personalized medicine for autoinflammatory and related diseases	61
International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiative	60
Chimeric receptors broaden the therapeutic landscape for autoimmune disease	59
Phase III trial of telitacicept in SLE	59
PGE2 receptor antagonist has potential to treat osteoarthritis	59
Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach	59